Overall, anti-VEGF agents used in treating ROP appear to be effective with a favorable safety profile; however, further randomized clinical trials are required to determine the preferred treatment, optimal dosing, and long-term ocular and systemic outcomes following treatment. Here, VEGFA is linked to retinopathy of prematurity.